Chindex International Inc. (CHDX, Financial) filed Quarterly Report for the period ended 2009-09-30.
Chindex International Inc. has a market cap of $218.49 million; its shares were traded at around $16.21 with a P/E ratio of 22.83 and P/S ratio of 1.27.
Expenses for the Healthcare Services division, including costs allocated from the parent company, increased 4% to $18,718,000 from $18,017,000 over the periods. Expenses for the division, excluding costs allocated from the parent company, increased by $681,000 primarily including cost of patient services ($331,000) and salary expense ($267,000). Salary expense represented 48% of division revenue in the recent period and 51% of revenue in the prior period. Cost allocated from the parent company to the division increased $20,000.
Expenses for the Medical Products division, including costs allocated from the parent company, increased 19% to $6,217,000 from $5,272,000 over the periods. Expenses for the division, excluding costs allocated from the parent company, increased by $325,000 including salary expense ($105,000), bad debt expense ($127,000) and selling expense ($119,000). Cost allocated from the parent company to the division increased $620,000, primarily stock-based compensation. The division had a loss from operations before foreign exchange gains of $1,481,000 in the recent period, compared with income from operations before foreign exchange gains of $582,000 in the prior period. In the current period, the impact of exchange rate fluctuations between the periods had a positive impact on loss from operations of approximately $25,000.
Our consolidated revenue for the six months ended September 30, 2009 was $83,451,000, up 19% from the six months ended September 30, 2008 revenue of $70,179,000. We recorded income from operations of $6,688,000 for the recent period, as compared to income from operations of $2,401,000 for the same quarter last year. We recorded net income of $3,791,000 for the recent period, as compared to net income of $700,000 for the same period last year.
Expenses for the Healthcare Services division, including costs allocated from the parent company, increased 5%, to $36,641,000 from $34,814,000 over the periods. Expenses for the division, excluding costs allocated from the parent company, increased by $1,656,000 primarily including increases of cost of patient services ($749,000), and salary expense ($1,404,000), offset by decreases in bad debt expense, professional fees, travel and other expenses. Salary expense represented 47% of division revenue in the recent period and 48% of revenue in the prior period. Cost allocated from the parent company to the division increased $172,000.
Expenses for the Medical Products division, including costs allocated from the parent company, increased 18% to $11,788,000 from $10,009,000 over the periods. Expenses for the division, excluding costs allocated from the parent company, increased by $1,044,000 including increases in salary expense ($1,026,000), offset by decreases in travel and other selling expenses. Cost allocated from the parent company to the division increased $735,000, primarily stock-based compensation. The division had a loss from operations before foreign exchange gains of $1,237,000 in the recent period, compared with loss from operations before foreign exchange gains of $1,554,000 in the prior period. In the current period, the impact of exchange rate fluctuations between the periods had a positive impact on loss from operations of approximately $91,000.
Read the The complete Report
Chindex International Inc. has a market cap of $218.49 million; its shares were traded at around $16.21 with a P/E ratio of 22.83 and P/S ratio of 1.27.
Highlight of Business Operations:
Our consolidated revenue for the three months ended September 30, 2009 was $38,119,000, unchanged from the three months ended September 30, 2008 revenue of $38,110,000. We recorded income from operations of $1,413,000 for the recent quarter, as compared to income from operations of $1,648,000 for the same quarter last year. We recorded net income of $538,000 for the recent quarter, as compared to net income of $862,000 for the same quarter last year.Expenses for the Healthcare Services division, including costs allocated from the parent company, increased 4% to $18,718,000 from $18,017,000 over the periods. Expenses for the division, excluding costs allocated from the parent company, increased by $681,000 primarily including cost of patient services ($331,000) and salary expense ($267,000). Salary expense represented 48% of division revenue in the recent period and 51% of revenue in the prior period. Cost allocated from the parent company to the division increased $20,000.
Expenses for the Medical Products division, including costs allocated from the parent company, increased 19% to $6,217,000 from $5,272,000 over the periods. Expenses for the division, excluding costs allocated from the parent company, increased by $325,000 including salary expense ($105,000), bad debt expense ($127,000) and selling expense ($119,000). Cost allocated from the parent company to the division increased $620,000, primarily stock-based compensation. The division had a loss from operations before foreign exchange gains of $1,481,000 in the recent period, compared with income from operations before foreign exchange gains of $582,000 in the prior period. In the current period, the impact of exchange rate fluctuations between the periods had a positive impact on loss from operations of approximately $25,000.
Our consolidated revenue for the six months ended September 30, 2009 was $83,451,000, up 19% from the six months ended September 30, 2008 revenue of $70,179,000. We recorded income from operations of $6,688,000 for the recent period, as compared to income from operations of $2,401,000 for the same quarter last year. We recorded net income of $3,791,000 for the recent period, as compared to net income of $700,000 for the same period last year.
Expenses for the Healthcare Services division, including costs allocated from the parent company, increased 5%, to $36,641,000 from $34,814,000 over the periods. Expenses for the division, excluding costs allocated from the parent company, increased by $1,656,000 primarily including increases of cost of patient services ($749,000), and salary expense ($1,404,000), offset by decreases in bad debt expense, professional fees, travel and other expenses. Salary expense represented 47% of division revenue in the recent period and 48% of revenue in the prior period. Cost allocated from the parent company to the division increased $172,000.
Expenses for the Medical Products division, including costs allocated from the parent company, increased 18% to $11,788,000 from $10,009,000 over the periods. Expenses for the division, excluding costs allocated from the parent company, increased by $1,044,000 including increases in salary expense ($1,026,000), offset by decreases in travel and other selling expenses. Cost allocated from the parent company to the division increased $735,000, primarily stock-based compensation. The division had a loss from operations before foreign exchange gains of $1,237,000 in the recent period, compared with loss from operations before foreign exchange gains of $1,554,000 in the prior period. In the current period, the impact of exchange rate fluctuations between the periods had a positive impact on loss from operations of approximately $91,000.
Read the The complete Report
